Summary Selective delivery of cytotoxic anti-neoplastic drugs can diminish the severe side-effects associated with these drugs. Many malignant tumours express high levels of low-density lipoprotein (LDL) receptors on their membranes. Therefore, LDL may be used as a carrier to obtain selective delivery of anti-neoplastic drugs to tumours. The present study was performed to investigate the feasibility of the murine B16 tumour/mouse model for the evaluation of LDL-mediated tumour therapy. LDL binds with high affinity to LDL receptors on cultured B16 cells (Kd, 5.9+2.3 Yg ml -; Bmax, 206+23 ng LDL mg-1 cell protein). After binding and internalisation, LDL was very efficiently degraded: 724+ 19 ng LDL mg -cell protein h-'. Chloroquine and ammonium chloride completely inhibited the degradation of LDL by the B16 cells, indicating involvement of lysosomes. LDL receptors were down-regulated by 70% after preincubation of B16 cells with 300 jg ml-l LDL, indicating that their expression is regulated by intracellular cholesterol. To evaluate the uptake of LDL by the B16 tumour in vivo, tissue distribution studies were performed in C57/Bl mice inoculated with B16 tumours. For these experiments, LDL was radiolabelled with tyramine cellobiose, a non-degradable label, which is retained in cells after uptake. At 24 h after injection of LDL, the liver, adrenals and the spleen were found to be the major organs involved in LDL uptake, with tissue-serum (T/S) ratios of 0.82+0.08, 1.17 + 0.20 and 0.69 + 0.08 respectively. Of all the other tissues, the tumour showed the highest uptake of LDL (T/S ratio of 0.40+0.07). A large part of the LDL uptake was receptor mediated, as the uptake of methylated LDL was much lower. Although the LDL uptake by the liver, spleen and adrenals is higher than that by the tumour, the LDL receptor-mediated uptake by these organs may be selectively down-regulated by methods that do not affect the expression of LDL receptors on tumour cells. It is concluded that the B16 tumour-bearing mouse constitutes a good model to evaluate the effectiveness of LDL-mediated delivery of cytotoxic (pro)drugs to tumours in vivo.
The lack of selectivity of anti-neoplastic drugs is a major problem associated with the chemotherapy of cancer. Often, the toxicity of these drugs causes severe side-effects, which preclude the administration of a fully effective dose for the treatment of malignancies. Selective delivery of these cytotoxic compounds to neoplastic cells would diminish the unwanted side-effects and accomplish more effective drug concentrations in the tumour. Several macromolecules and particulate systems have been proposed as carriers for the selective delivery of anti-tumour drugs. Among them are monoclonal antibodies (Trail et al., 1993) , liposomes (Fan et al., 1990) , microspheres, growth factors and hormones (Tomlinson, 1987 ). An interesting endogenous carrier is low-density lipoprotein (LDL), the predominant cholesteroltransporting lipoprotein in man. LDL is a spherical particle of about 23 nm, with a core of neutral lipids of mainly cholesterol esters, and a shell consisting of a monolayer of phospholipids and cholesterol. As a variety of lipophilic compounds can be incorporated in the apolar core, LDL may be used as a carrier for lipophilic drugs (Counsell and Pohland, 1982, and reviewed by Firestone, 1994) . A large part of the surface of the particle is covered with apoprotein B, which is recognised by specific LDL receptors on cells. LDL is bound by the LDL receptor, internalised and degraded in lysosomes. The released cholesterol is used for the synthesis of cell membranes and, in some cell types, steroid hormones and bile acids. In general, about 75% of the uptake of LDL by cells is mediated by the LDL receptor (Goldstein and Brown, 1977) . The receptor-mediated uptake of LDL is often determined by the cell's need for cholesterol. Fast-growing cells, such as tumour cells, need large amounts of cholesterol to synthesise new membranes. Indeed, results from many studies indicate that a variety of tumour cells have a higher expression of LDL receptors than the corresponding normal cells (Firestone, 1994) . Evidence for a high expression of LDL receptors on tumour cells was obtained by measuring binding and processing of LDL by tumour cells in culture. Additional evidence came from clinical studies in which a correlation was established between increased clearance of LDL from the circulation and tumour burden. Especially tumours of gynaecological origin and myeloid leukaemic cells, but also colon, kidney, lung and brain tumours, were found to express exceptionally high amounts of LDL receptors (Firestone, 1994) . The high expression of LDL receptors on this variety of malignant cells makes LDL an attractive carrier for receptor-mediated delivery of anti-neoplastic drugs to tumours.
In a number of studies it was shown that lipophilic drug molecules could be incorporated in LDL particles without affecting the recognition of the particles by the LDL receptor. Furthermore, killing of cultured tumour cells was achieved with various drug-LDL complexes (Vitols et al., 1985; Firestone et al., 1984; Tokui et al., 1994; Mosley et al., 1981; Lundberg, 1993 , Lestravel-Delattre et al., 1992 . However, to evaluate further the potential clinical application of LDLmediated selective drug delivery to tumours in vivo, it is essential to develop an appropriate tumour-bearing animal model. In a few earlier studies, the association of radioiodinated LDL with tumours was studied in tumour-bearing mice (Norata et al., 1984; Lombardi et al., 1989; Hynds et al., 1984 
Isolation of lipoproteins
Human LDL (density 1.024-1.063 g ml-1) and high-density lipoprotein (HDL) (density 1.063-1.210 g ml-') were isolated from the serum of healthy fasted volunteers by density ultracentrifugation according to Redgrave et al. (1975) . HDL was subsequently depleted of apoprotein E-containing particles, using a Sepharose -heparin column BSA, followed by two washes with the same buffer without BSA. The cells were then lysed with 1 ml of 0.1 N sodium hydroxide, and the amounts of protein and radioactivity in the lysate were determined. The amount of cell protein was determined by the method of Lowry et al. (1951) with BSA as standard.
Association and degradation To determine association and degradation of ['25I ]LDL the cells were incubated with the radiolabelled ligand and the indicated additives at 37°C. After the incubation, the culture plates were placed on ice and 0.5 ml of the medium was taken to measure the amounts of released degradation products of ['25I ]LDL according to the method described earlier by van Berkel et al. (1981) . The cell-associated radioactivity was determined as described above for cell-bound radioactivity.
Regulation of receptor expression For the experiments on the LDL receptor regulation on B16 cells, the cells were, after the initial 18 h of preincubation with preincubation medium (1% BSA), incubated for another 24 h with preincubation medium containing increasing amounts of LDL or HDL. Then the cells were washed at 37°C (for 10, 10 and 30 min) with preincubation medium without additions. The experiments were started by adding preincubation medium containing 10 jug ml-' ['251]LDL. After 3 h, the plates were placed on ice and association and degradation were determined as described above. 
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The selectivity of the association and degradation was investigated in a competition experiment (Figure 3 ). The cells were incubated at 37°C with [125I]LDL in the presence of increasing amounts of unlabelled LDL or methylated LDL. Reductive methylation of only 20% or more of the lysine residues on the apoprotein B molecule prevents the receptor recognition of LDL, without changing other physicalchemical parameters of the particle (Weisgraber et al., 1978) . The results presented in Figure 3 clearly indicate that unlabelled LDL competes with [125I]LDL for binding to the receptor. The cell association was decreased to less than 15% of the control value by the addition of 200 jug ml-' of unlabelled LDL. Methylated LDL, however, did not compete with the iodinated LDL, even at high concentrations.
Chloroquine and ammonium chloride inhibit the lysosomal degradation of internalised proteins by raising the pH inside lysosomes (Seglen et al., 1979) . Both compounds were used to establish the involvement of the lysosomes in the degradation of LDL by the B16 cells. The association of ['251 ]LDL by B1 6 cells was relatively unaffected by the addition of the lysosomotropic compounds (Figure 4a) . However, the degradation of [125I]LDL could be completely inhibited by these agents (Figure 4b ), indicating that the LDL is processed in B16 cells via the lysosomal route.
It has been shown earlier for a number of cell types that the binding of LDL to its receptor is strictly Ca2" dependent (Goldstein and Brown, 1977) . Figure 5 shows that the receptor-mediated association and degradation of [125I]LDL by B16 cells is also Ca2+ dependent. Both association and degradation were inhibited when the incubation medium was virtually completely depleted of Ca2 . Only 0.2 mM Ca'+ was sufficient to accomplish association and degradation of the ligand.
Regulation of the expression of LDL receptors on B16 cells To study the ability of the B16 cells to adapt to changes in the supply of LDL, the regulation of the expression of the LDL receptor on these cells was investigated. In these studies, the cells were preincubated with increasing amounts of LDL. After the preincubation period, the expression of LDL Figure 7 . Tissue -serum ratios are expressed as the uptake of LDL per g of organ divided by the amount of LDL per g of serum (density: 1.05 g ml-'). As has been found earlier in other species (Dietschy et al., 1993) twice the amount of label in the liver, which is in good agreement with the previously reported data.
Discussion
A variety of tumour cell types express high numbers of LDL receptors, which makes LDL a very interesting carrier for the selective delivery of drugs to these tumour cells. In this study, we explored the feasibility of using the murine B16 melanoma cell line for the evaluation of the effectiveness of LDLmediated tumour therapy. For this purpose, we characterised the binding and processing of LDL by B16 cells in culture and we studied the uptake of LDL by B 16 tumours inoculated in mice. We found that B16 cells in culture specifically bind LDL with high affinity (Kd = 5.9 jug ml -). Since the B16 cells bound maximally 206 ng of LDL per mg cell protein, which corresponds to approximately 220 000 LDL receptors per cell, the affinity of binding of LDL to the B16 cells is very similar to the affinity of binding of LDL to human parenchymal cells (Kd =S ,g ml-1; Kamps et al., 1991) . However, the human parenchymal cells bound under similar experimental conditions much less LDL (75 ,ug ml-' of cell protein). The requirements for the interaction of LDL with the receptors on the B 16 cells are very similar to those of the 'classical' LDL receptors described by Brown and Goldstein, (1977) . The lysine residues of LDL were found to be essential for the interaction with the receptor, as methylation of LDL competely abolished the capacity of the particle to compete for binding to the receptor. Further, the receptor-mediated association and degradation of LDL were Ca2-dependent.
For an efficient intracellular delivery of drugs by an LDL carrier, it is essential that the carrier is not only recognised, but also activity internalised by the cells. B 16 cells were found to internalise and degrade LDL efficiently. The al., 1987; Havekes et al., 1986) . In contrast, human fibroblast cells were found to be more sensitive to receptor regulation, since preincubation of fibroblasts with as little as 20 jug ml-1 of LDL led to a 75% decrease in LDL binding (Brown and Goldstein, 1975) , indicating a relatively autonomic behaviour of the tumour compared with fibroblasts.
To evaluate the uptake of LDL by the B16 tumour in vivo, B16 cells were implanted in C57/BL6 mice and the tissue distribution of intravenously injected [12"I]TC-LDL was studied. In agreement with earlier studies on LDL catabolism in vivo (Dietschy et al., 1993; Moerlein et al., 1988) , the liver (maintaining the cholesterol homeostasis), the adrenals (production of steroid hormones), the spleen and the intestinal tract were the major sites of recovery of LDL. The lower uptake of [125I]TC-MeLDL by the liver, spleen and adrenals indicates that the uptake of LDL by these organs is mainly LDL receptor-mediated. The accumulation of LDL in the intestinal tract after 24 h is probably a consequence of reported earlier for 125I-TC-labelled LDL and asialofetuin injected into rats (Pittman et al., 1983; Kleinherenbrink-Stins et al., 1990) . Of all other tissues, the tumour showed the highest uptake of LDL, and the uptake by the B16 tumour was mainly LDL receptor-mediated.
The observed ratio of uptake of ['25I]TC-LDL by the B16 tumour vs uptake by the liver was 0.48+0.06. In previous studies, using [1251I] LDL, tumour-liver ratios of 1.5-2 were found (Lombardi et al., 1989; Ponty et al., 1993 (Angelin et al., 1983) . The expression of LDL receptors on tumour cells, which lack remnant receptors, will be unaffected by the diet. Further, the expression of LDL receptors in the liver, but also in the spleen, can be down-regulated by the administration of bile salts, like cholic acid or taurocholate. Uptake of LDL by tumour cells was found to be unaffected by the treatment (Hynds et al., 1984) . The uptake of LDL by the adrenals was shown to be greatly reduced in rats and rabbits by the administration of corticosteroids like hydrocortisone or dexamethasone (Hynds et al., 1984; Isaacsohn et al., 1986 ). Thus, it is possible specifically to down-regulate LDL receptors on non-malignant cells, so that cytotoxic compounds can be selectively delivered to tumour cells by an LDL carrier.
In conclusion, we have shown that cultured murine B16 tumour cells bind and internalise LDL via specific LDL receptors. The rate of internalisation of LDL was found to be sufficiently high to allow a significant intracellular accumulation of drugs incorporated in LDL carriers. B16 tumours inoculated in mice take up substantial amounts of circulating LDL via their LDL receptors. Liver, spleen and adrenals also show a high uptake of LDL, but LDL receptors in these organs can be specifically down-regulated, without affecting the expression of LDL receptors on tumour cells. We conclude that B16 tumour-bearing mice constitute a good animal model to evaluate the feasibility of LDL-mediated tumour targeting.
